Astute Medical

Astute Medical has entered into a strategic collaboration with Ortho-Clinical Diagnostics (OCD) that will expand access to a new test that evaluates critically ill patients for risk of acute kidney injury (AKI), a prevalent and deadly condition.

According to a study recently published in the Journal of the American Society of Nephrology, AKI could be more deadly than heart attack.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

As part of the multi-year deal, Astute Medical has designated OCD as the exclusive sales agent for Astute’s NephroCheck Test and Astute140 Meter in certain countries of the EU and in the US if approved.

Currently, the NephroCheck Test and the Astute140 Meter are not available for sale in the US and the company is pursuing regulatory clearance to market both in the country.

In addition, OCD also secured a semi-exclusive worldwide licence to develop and commercialise a version of the NephroCheck Test for use on its VITROS line of automated, high-volume testing platforms.

According to the company, the test developed for the OCD platform will require separate regulatory clearances before it can be sold.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData
"We believe there is a tremendous unmet need for improved tools in AKI ."

Astute Medical chief executive officer Chris Hibberd said: "We believe there is a tremendous unmet need for improved tools in AKI and are delighted to be working with OCD to address this important medical condition."

OCD chairman and chief executive officer Martin Madaus said: "Astute’s innovative approach and product is a perfect fit with the commercial strength of OCD and our desire to advance important new diagnostic tests."

Both the firms have not disclosed further financial details of the agreement, under which OCD has made a $15m equity investment in Astute Medical.

Astute’s current areas of interest include abdominal pain, acute coronary syndromes, cerebrovascular injury, kidney injury and sepsis.

Image: Currently, Astute’s NephroCheck Test and the Astute140 Meter are not available for sale in the US. Photo: courtesy of Astute Medical.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact